Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Zhou%2C+Keshu%22&type=Person&sort=year
/vufind/Search/Results?lookfor=%22Zhou%2C+Keshu%22&type=Person&sort=year
Search /vufind/Search2/Results?lookfor=%22Zhou%2C+Keshu%22&type=Person&sort=year
PubPharm (71)
1
Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma
enthalten in:
Leukemia & lymphoma
| 2024
von
Song, Y.
|
Li, J.
|
Zhou, K.
| +9
Wird geladen...
2
Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia
enthalten in:
Cancer
| 2024
von
Wang, X.
|
Zhang, B.
|
Zhang, Q.
| +17
Wird geladen...
3
Dual-targeted CAR T-cell immunotherapies for hematological malignancies : latest updates from the 2023 ASH annual meeting
enthalten in:
Experimental hematology & oncology
| 2024
von
Yang, J.
|
Guo, H.
|
Han, L.
| +2
Wird geladen...
4
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
enthalten in:
Haematologica
| 2024
von
Song, Y.
|
Cao, J.
|
Zhang, Q.
| +25
Wird geladen...
5
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B) : a single-arm, multinational, phase 2 study
enthalten in:
The Lancet. Oncology
| 2024
von
Song, Y.
|
Malpica, L.
|
Cai, Q.
| +30
Wird geladen...
6
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma : A phase 2, multicenter, open-label study
enthalten in:
American journal of hematology
| 2023
von
Deng, L.
|
Li, Z.
|
Zhang, H.
| +30
Wird geladen...
7
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma : final analysis of the MAGNOLIA study
enthalten in:
Blood advances
| 2023
von
Opat, S.
|
Tedeschi, A.
|
Hu, B.
| +23
Wird geladen...
8
Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2
enthalten in:
Biochemical and biophysical research communications
| 2023
von
Yang, H.
|
Liu, Y.
|
Yang, J.
| +4
Wird geladen...
9
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma : An updated pooled analysis
enthalten in:
Cancer medicine
| 2023
von
Song, Y.
|
Zhou, K.
|
Zou, D.
| +19
Wird geladen...
10
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab : a multicenter open-label phase 2 study
enthalten in:
Blood advances
| 2023
von
Bachy, E.
|
Savage, K.
|
Huang, H.
| +28
Wird geladen...
1
2
3
4
5
6
7
8
Nächster »
[8]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
71
Aufsätze
62
E-Artikel
62
E-Ressourcen
9
Gedruckte Aufsätze
Zeitschriftentitel
8
Advances in therapy
7
Leukemia & lymphoma
6
Experimental hematology & oncology
4
Investigational new drugs
4
Journal of hematology & oncology
3
Clinical cancer research : an official journal ...
3
Frontiers in oncology
3
Platelets
2
American journal of hematology
2
Blood advances
2
Experimental hematology
2
Frontiers in immunology
2
Genetics in medicine
2
OncoTargets and therapy
2
Zhonghua xue ye xue za zhi = Zhonghua xueyexue ...
1
Aging
1
American Journal of Hematology
1
Annals of translational medicine
1
Biochemical and biophysical research communicat...
1
Blood
Alle anzeigen ...
weniger ...
Thema
45
Journal Article
26
Research Support, Non-U.S. Gov't
12
Zanubrutinib
11
zanubrutinib
10
AG9MHG098Z
10
Clinical Trial, Phase II
9
Protein Kinase Inhibitors
8
Piperidines
7
Multicenter Study
7
Pyrazoles
6
EC 2.7.10.2
5
Antineoplastic Agents
5
B-cell lymphoma
5
DLBCL
5
Pyrimidines
4
Agammaglobulinaemia Tyrosine Kinase
4
BTK inhibitors
4
Biosimilar
4
CHOP
4
CLL/SLL
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
54
2020-
17
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
65
Englisch
2
Chinesisch
Haven't found what you're looking for?
Wird geladen...